Drug Eluting Stent News and Research

RSS

A drug-eluting stent (DES) is a coronary stent (a scaffold) placed into narrowed, diseased coronary arteries that slowly releases a drug to block cell proliferation. This prevents fibrosis that, together with clots (thrombus), could otherwise block the stented artery, a process called restenosis.

Antiplatelet monotherapy appears to be safer but does not reduce risk of heart attack

Long-term antiplatelet monotherapy after stenting is safe but does not reduce the risk of death or heart attack compared to standard dual antiplatelet therapy, according to late breaking results from the GLOBAL LEADERS trial presented today in a Hot Line Session at ESC Congress 2018 and published in The Lancet.

27 Aug 2018

New clinical trial shows safety and efficacy of second generation drug-eluting stents

Results of the PERSPECTIVE trial were presented today as late-breaking clinical science at the Society for Cardiovascular Angiography and Interventions 2018 Scientific Sessions.

26 Apr 2018

Patients given six-month dual antiplatelet therapy have increased heart attack risk

The combined rate of death from any cause, heart attack or stroke within 18 months was not significantly different in patients with acute coronary syndrome who were randomly assigned to receive dual antiplatelet therapy for either six months or at least 12 months after receiving a drug-eluting stent.

13 Mar 2018

Expert encourages cardiologists to continue using conventional drug-eluting stents

In a New England Journal of Medicine editorial published last week, Debabrata Mukherjee, M.D., provides expert commentary on bioresorbable stents, an alternative to the traditional stents used in patients with cardiac conditions.

6 Apr 2017

New app helps heart patients with drug-eluting stents adhere to medications, study finds

A tablet computer application helped heart patients with drug-eluting stents take their medications correctly, a study has found.

20 Jan 2017

Stents can be as effective as surgery for many patients with left main coronary artery disease

A major international study has found that drug-eluting stents, a less-invasive alternative to bypass surgery, are as effective as surgery for many patients with a blockage in the left main coronary artery.

1 Nov 2016

Study shows non-inferiority of short-term dual antiplatelet therapy in patients with DES placement

A short-term course of dual antiplatelet therapy (DAPT) is non-inferior to a longer course in patients who have undergone placement of a particular kind of drug-eluting stent (DES), researchers reported here.

29 Aug 2016

JACC publishes pivotal data on Tryton’s dedicated coronary bifurcation stent, results submitted to FDA

Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, today announced that results from the Tryton Confirmatory Study of the company’s Side Branch Stent have been published in JACC Cardiovascular Interventions.

6 Jul 2016

PCI with polymer-free BA9 drug-coated stent better than bare metal stent in ACS patients

Patients with acute coronary syndromes (ACS) who are at high risk for bleeding have significantly lower rates of target lesion revascularisation and fewer adverse events after undergoing percutaneous coronary intervention (PCI) with a polymer-free biolimus-A (BA9) drug-coated stent than with those receiving a bare metal stent (BMS) in results from a sub-study of the LEADERS FREE trial reported for the first time in a late-breaker session at EuroPCR 2016.

17 May 2016

Medinol announces completion of enrollment in BIONICS trial to evaluate effectiveness of eDES

Medinol, a developer of Interventional Cardiology devices, announced today the completion of enrollment in its BIONICS trial, a global, prospective, randomized, multicenter, clinical trial designed to evaluate the safety and effectiveness of a new Coronary Stent System, the first ever elastomeric Drug Eluting Stent or eDES.

22 Sep 2015

Abbott reports positive results of ABSORB Japan study comparing efficacy of fully dissolving heart stent to XIENCE

Abbott (NYSE: ABT) announced today positive one-year clinical results from ABSORB Japan, a multi-center, randomized trial comparing the safety and effectiveness of Abbott's fully dissolving Absorb™ heart stent to XIENCE ®, Abbott's market-leading, permanent drug eluting stent.

1 Sep 2015

Radial approach superior than femoral one for coronary angiography and PCI for ACS patients

For the first time, ESC Guidelines published today give the highest degree of recommendation for the radial approach over the femoral one for coronary angiography and percutaneous coronary intervention (PCI) in patients with acute coronary syndromes (ACS).

29 Aug 2015

ESC Congress to highlight results from global trials in six press conferences

Members of the press will be the first to hear the highly anticipated results from global trials in six press conferences devoted to hot lines research.

13 Aug 2015

Mount Sinai launches clinical trial to test effectiveness of ticagrelor drug in treating coronary stent patients

The Icahn School of Medicine at Mount Sinai has launched an international clinical trial called TWILIGHT to test the safety and effectiveness of treating coronary stent patients with the anti-clotting medication ticagrelor alone, instead of combining it with aspirin, which is the current standard of care. Researchers will analyze the potential benefits of administering ticagrelor to reduce clotting while at the same time reducing the risk of bleeding associated with the use of both medications.

12 Aug 2015

Biosensors’ Q1 FY16 revenue reduces US$67.0M compared to US$80.2M in Q1 FY15

Biosensors International Group, Ltd., a developer, manufacturer and marketer of innovative medical devices, today announced financial results for its first fiscal quarter ended 30 June 2015 ("Q1 FY16").

3 Aug 2015

Survey: 52% of acute coronary syndrome patients don't take their prescribed OAP therapy

People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent are prescribed an oral antiplatelet (OAP) therapy and aspirin to help prevent a heart attack, a blood clot in their heart stent (stent thrombosis), or even death.

28 Apr 2015

Cardiac catheterization performed through wrist can reduce bleeding, lower mortality

The groin is the usual access point for investigating or treating the heart with a catheter, but using the wrist as access point reduces bleeding and lowers mortality. These findings are from an international study with major involvement from the University of Bern published today in the Lancet.

19 Mar 2015

Extended dual antiplatelet therapy after DES implantation increases mortality

Data from a meta-analysis published today in The Lancet found that extended duration dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation was associated with significantly higher rates of mortality compared to shorter DAPT.

18 Mar 2015

Patients with multiple narrowed arteries have better outcomes with CABG than with PCI

Despite the advent of a new generation of stents, patients with multiple narrowed arteries in the heart who received coronary artery bypass grafting fared better than those whose arteries were opened with balloon angioplasty and stents in a study presented at the American College of Cardiology's 64th Annual Scientific Session.

17 Mar 2015

Cook Medical receives CE Mark for new thumbwheel deployment system for Zilver PTX drug-eluting peripheral stent

CE Mark has been awarded to the new rotating thumbwheel deployment system for Cook Medical’s Zilver PTX drug-eluting peripheral stent. The new system, which is now available for purchase in the UK, Ireland, Germany, Spain and Italy, provides simple deployment for the world’s first and only approved drug-eluting stent for the superficial femoral artery (SFA).